Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab

admin

8 years ago

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab in CLL